CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

1997 • 995 citations

The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

1992 • 456 citations

Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites

1992 • 417 citations

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1985 • 386 citations

The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects

1990 • 367 citations

Venlafaxine oxidation in vitro is catalysed by CYP2D6

1996 • 226 citations

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

1994 • 196 citations

Pharmacokinetics of Desipramine Coadministered With Sertraline or Fluoxetine

1994 • 191 citations

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1993 • 189 citations

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1992 • 168 citations

Fluoxetine: A Serotonin‐specific, Second‐generation Antidepressant

1987 • 151 citations

Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.

1994 • 151 citations

Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects

1993 • 135 citations

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study

1997 • 124 citations

Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive Metabolizers

1997 • 118 citations

A fluvoxamine-caffeine interaction study

1996 • 104 citations

Fluvoxamine Versus Clomipramine for Obsessive-Compulsive Disorder

1996 • 104 citations

The debrisoquine hydroxylation test predicts steady‐state plasma levels of desipramine.

1983 • 93 citations

Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.

1990 • 90 citations

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

1984 • 82 citations

Antidepressant Drug Interactions and the Cytochrome P450 System: A Critical Appraisal

1995 • 81 citations

LIVING AND DYING IN THE NINETEENTH CENTURY.

1963 • 69 citations

CYP2D6 Inhibition in Patients Treated With Sertraline

1997 • 59 citations

A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major Depression

1996 • 51 citations

A Pharmacokinetic Evaluation of the Combined Administration of Triazolam and Fluoxetine

1992 • 50 citations

Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder

1997 • 46 citations

Chlorpheniramine plasma concentration and histamine H1-receptor occupancy*

1995 • 32 citations

Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine.

1989 • 25 citations

Treating Depression: Potential Drug Interactions

1997 • 11 citations

Intraindividual Variability of the Dextromethorphan/Dextrorphan (DM/DP) Ratio in Extensive Metabolizers

1996 • 6 citations